Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

1.35USD
6:04pm BST
Change (% chg)

$-0.02 (-1.46%)
Prev Close
$1.37
Open
$1.38
Day's High
$1.40
Day's Low
$1.35
Volume
12,175
Avg. Vol
103,890
52-wk High
$8.10
52-wk Low
$1.23

Latest Key Developments (Source: Significant Developments)

Aduro Biotech Announces Clinical Program Update For Anti-April Antibody Bion-1301
Wednesday, 15 May 2019 

May 15 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH ANNOUNCES CLINICAL PROGRAM UPDATE FOR ANTI-APRIL ANTIBODY BION-1301.ADURO BIOTECH INC - 95% TARGET ENGAGEMENT ACHIEVED AND MAINTAINED; NO OBJECTIVE RESPONSES OBSERVED IN MM PATIENT SETTING.ADURO BIOTECH - RESULTS FROM DOSE ESCALATION PART OF PHASE 1/2 STUDY WAS WELL TOLERATED ACROSS WIDE DOSE RANGE & NO DOSE LIMITING TOXICITIES OBSERVED.  Full Article

Aduro Biotech CFO Jennifer Lew Notified Co Of Intent To Resign
Tuesday, 7 May 2019 

May 7 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH - ON MAY 3, 2019, JENNIFER LEW, CHIEF FINANCIAL OFFICER OF ADURO BIOTECH NOTIFIED CO OF HER INTENT TO RESIGN EFFECTIVE MAY 24, 2019.ADURO BIOTECH INC - INITIATING A SEARCH FOR LEW'S SUCCESSOR..  Full Article

Lilly and Aduro Biotech announce research collaboration and license agreement to develop novel immunotherapies
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Aduro Biotech Inc ::LILLY AND ADURO BIOTECH ANNOUNCE RESEARCH COLLABORATION AND LICENSE AGREEMENT TO DEVELOP NOVEL IMMUNOTHERAPIES.ADURO BIOTECH INC - ADURO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ADURO BIOTECH INC - WILL BE ELIGIBLE FOR DEVELOPMENT AND COMMERCIAL MILESTONES UP TO ABOUT $620 MILLION PER PRODUCT.ADURO BIOTECH - THERE WILL BE NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF TRANSACTION.ADURO-TO RECEIVE RESEARCH FUNDING DURING RESEARCH TERM,HAS OPTION TO CO-FUND CLINICAL DEVELOPMENT OF EACH PRODUCT IN EXCHANGE FOR INCREASE IN ROYALTY PAYMENTS.  Full Article

Aduro Biotech Reports Q3 Loss Per Share Of $0.29
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.29.Q3 REVENUE $3.1 MILLION VERSUS $3.8 MILLION.Q3 REVENUE VIEW $4.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.ADURO BIOTECH - CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES TOTALED $278.6 MILLION AT SEPT 30, 2018, COMPARED TO $349.7 MILLION AT DEC 31, 2017.  Full Article

Aduro Biotech Q4 Loss Per Share $0.34
Thursday, 1 Mar 2018 

March 1 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $3.8 MILLION VERSUS $3.9 MILLION.Q4 LOSS PER SHARE $0.34.  Full Article

Aduro Biotech Announces Management Changes
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER.ADURO BIOTECH ANNOUNCES MANAGEMENT CHANGES.ADURO BIOTECH - GREGORY SCHAFER WILL BE STEPPING DOWN AS CHIEF OPERATING OFFICER IN EARLY MARCH.  Full Article

Aduro Biotech Provides Update On CRS-207 Programs
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH PROVIDES UPDATE ON CRS-207 PROGRAMS.COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207.COMPANY WILL WIND DOWN EACH OF ITS TRIALS IN MESOTHELIOMA, OVARIAN AND GASTRIC CANCER FOR CRS-207.EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO FUND PLANNED ACTIVITIES FOR NEXT THREE YEARS THROUGH 2020.  Full Article

Aduro Biotech reports Q3 loss per share $0.33
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Aduro Biotech Inc ::Aduro Biotech reports third quarter 2017 financial results.Q3 loss per share $0.33.Q3 revenue $3.8 million versus $3.8 million.Q3 revenue view $6.1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Aduro Biotech Inc - ‍ anticipated 2017 milestones include to initiate phase 1 multiple myeloma trial with bion-1301, an anti-April antibody​.  Full Article

Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Aduro Biotech Inc :Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology.Aduro Biotech Inc - ‍trial is seeking to enroll approximately 10 patients with metastatic colorectal cancer that is MSS​.  Full Article

BRIEF-Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study

* ADURO BIOTECH AND NOVARTIS PRESENT RESULTS FROM ONGOING PHASE 1B STUDY OF STING AGONIST ADU-S100 (MIW815) IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY SPARTALIZUMAB (PDR001) IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS